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ABSTRACT 
Background 
The combined oral contraceptive pill is the preferred method of contraception for many 
women. However, women living with HIV often need to dose adjust their contraception due 
to drug drug interactions with antiretrovirals. The concentration of ethinylestradiol (EE) is 
increased by unboosted atazanavir (ATV), and decreased by ATV/ritonavir (while progestin 
exposure is increased and may lead to side effects). Therefore, if an oral contraceptive is 
administered with ATV/r, it must contain at least 30μg of EE and strict compliance is 
necessary. However, data on ATV boosted by cobicistat (ATV/c) are not yet available. 
 Methods 
This phase 1, open label, 57 day, cross over, PK study, enrolled healthy female volunteers 
aged 18-35 years, who were randomized to: i) group 1 received EE/levonorgestrel (LNG) - 
Microgynon, alone on days 1-21, EE/LNG (21 days) + ATV/c (14 days) in the co-
administration phase (days 22-43) and ATV/c alone on days 43-56; ii) group 2 received 
ATV/c alone on days 1-21, EE/LNG (21 days) + ATV/c (14 days) in the co-administration 
phase (days 22-43) and EE/LNG alone on days 43-56. Each group underwent intensive PK 
sampling on days 14, 35 and 56, and EE/LNG concentrations were measured by LC/MS. 
Results 
Of 16 healthy female volunteers screened, 13 were enrolled (1 was not eligible and 2 
withdrew consent for personal reasons) and 6 completed all PK phases (5 withdrew consent 
because of gastrointestinal adverse events, fatigue or rash). Geometric mean ratios (GMR, 
with vs without ATV/c) and 90% confidence intervals (CI) of EE Cmax, AUC, C24h were 1.05 
(0.92-1.19), 1.01 (0.83-1.22), 0.75 (0.60-0.93). GMR and CI (90%) of LNG Cmax, AUC, C24h 
were 0.83 (0.68-1.02), 0.92 (0.71-1.18), 1.01 (0.73-1.38). No grade 3 or 4 adverse events 
or laboratory abnormalities were observed in the women who completed the study. 
Conclusions 
Our findings show that EE C24h decreased by only 25% with ATV/cobicistat (versus 37% 
with ATV/ritonavir in previous studies). For the first time LNG PK was investigated during 
co-administration with cobicistat and no significant changes in its concentrations were 
measured. 
  
BACKGROUND 
 
Women account for slightly more than half of the world’s 36.7 million people living with 
HIV/AIDS1 and the majority are of childbearing age. Early and sustained HIV viral load 
suppression with antiretroviral (ARV) therapy now enables longer, healthier lives in women 
living with HIV (WLWH), with negligible risks of sexual/perinatal HIV transmission and 
improved fertility.2-5 A significant number of WLWH, however, report wanting to delay or 
avoid pregnancy,2, 6 meaning that access to safe and reliable contraception in the context 
of ARV is a critical aspect of HIV care for women and couples alike.7 The combined oral 
contraceptive pill (COCP) is the preferred method of contraception for many women 
worldwide.8, 9 It is also used to treat pre-menstrual disorders, heavy and painful menstrual 
bleeding, some benign breast disorders and may be beneficial in some women with acne.10 
However, WLWH are often unable to use hormonal contraception (HC) due to drug drug 
interactions (DDIs) with ARVs.11 DDIs may reduce contraceptive efficacy, thereby risking 
unintended pregnancy;10, 12 it may also lower ARV efficacy potentially leading to virological 
rebound, ARV resistance and increased risk of HIV transmission13 and it may increase drug 
levels leading to toxicity; all of which have consequences for women’s health and for their 
partners and children.14, 15 There is now good evidence that there is no risk of sexual HIV 
transmission when a person living with HIV has achieved sustained viral suppression on 
ARVs,5 meaning that many HIV serodifferent couples chose not to use condoms to prevent 
HIV transmission and rely on a hormonal method for contraception.2, 16 As WLWH are now 
in a position to re-evaluate their reproductive choices,17 it is essential to define the 
pharmacokinetics (PK) and pharmacodynamics (PD) of individual ARVs co-administered 
with HC to inform guidelines and ensure that efficacy and safety of contraceptives and ARVs 
are maintained. 
Boosted protease inhibitors (PI/b) such as atazanavir (ATV)/ritonavir have been used for 
many years and are an instrumental option for third agents in the management of HIV, 
thanks to once daily dosing and a high genetic barrier.18 Drug interactions between COCP 
and PIs boosted by ritonavir have been described.17 The concentration of ethinylestradiol 
(EE) is reported to increase with unboosted ATV (48% increase in area under the curve, 
AUC),19 and decrease with ATV/ritonavir (16% decrease in maximum concentration (Cmax,) 
19% in AUC and 37% in minimum concentration (Cmin)  of EE).20 This has been explained 
by the fact that the increase in exposure of ATV caused by ritonavir (which would be 
expected to increase the AUC of EE through cytochrome P450 (CYP) 3A4 and CYP2C9 
inhibition) is countered by ritonavir’s concomitant induction of glucuronidation (via uridine-
diphosphate glucuronosyltransferase 1A1 – UGT1A1) responsible for EE clearance.17 
The exposure of progestins studied to date (norgestimate and norethindrone) increases 
with unboosted and ritonavir boosted ATV co-administration, which has the potential to lead 
to side effects.20, 21 
Therefore, according to guidelines,22 if an oral contraceptive is administered with ATV/r, it 
must contain at least 30 μg of EE and strict compliance is necessary.20 However, data on 
ATV boosted by cobicistat are not yet available. 
Cobicistat is a more recently approved alternative pharmacological booster. Its molecular 
properties offer the opportunity for co-formulation with PIs into a fixed dose combination23 
and it is available co-formulated with ATV as Evotaz®.24 It has no ARV activity; however, it 
is a potent CYP3A4 inhibitor but unlike ritonavir, it is not a UGT1A1 inducer.23  
The aim of this study was to investigate the steady state PK of EE/levonorgestrel  (LNG) 
30/150 mcg (Microgynon®) and ATV/cobicistat 300/150 mg (Evotaz®) co-administration in 
HIV negative female healthy volunteers and to assess its safety and tolerability. 
  
PARTICIPANTS AND METHODS 
 
Participants 
Written informed consent was obtained from non-pregnant and non-lactating female healthy 
volunteers aged between 18 and 65 years with a body mass index (BMI) between 18 and 
35 kg/m2. Participants were excluded if they had any significant acute or chronic medical 
illness; abnormal physical examination, ECG or clinical laboratory determinations; positive 
screens for HIV, hepatitis B or C; current or recent (within three months) gastrointestinal 
disease; clinically relevant alcohol or drug use that the investigator felt would adversely 
affect compliance with trial procedures; exposure to any investigational drug or placebo 
within three months of the first dose of the study drug; use of any other drugs, including 
over the counter medications and herbal preparations, within two weeks of the first dose of 
the study drug; and previous allergy to any of the constituents of the pharmaceuticals 
administered during the trial. Women of childbearing potential required a negative 
pregnancy test at screening and baseline. 
 
Study design 
This was an open-label, crossover, 57-day (excluding screening and follow-up) phase 1 PK 
trial carried out at the Clinical Trial Unit of the St. Stephen’s Centre, Chelsea and 
Westminster Hospital, London, United Kingdom.  
At screening, clinical assessment and routine laboratory investigations were performed in 
all participants. The safety and tolerability of study medications were evaluated throughout 
the trial (on days 7,14, 28, 35, 49, 56 and at follow-up) using the National Institute of Allergy 
and Infectious Diseases (NIAID) Division of AIDS table for grading the severity of adult and 
pediatric adverse events to characterize abnormal findings (2004), vital signs, physical 
examinations and clinical laboratory investigation.  
After successful screening, volunteers were randomized to: i) group 1 received EE/LNG 
alone on days 1-21, EE/LNG (21 days) + ATV/cobicistat (14 days) in the co-administration 
phase (days 22-43) and ATV/cobicistat alone on days 43-56 (14 days); ii) group 2 received 
ATV/cobicistat alone on days 1-14, EE/LNG (21 days) + ATV/cobicistat  (14 days) in the co-
administration phase (days 22-43) and EE/LNG alone on days 43-56 (14 or 21 days, patient 
choice). Each group underwent intensive PK sampling on study days 14, 35 and 56 to 
measure plasma concentrations of EE/LNG and/or ATV/cobicistat at 0 (pre-dose), 2, 4, 8, 
12, 24 hours post dose. On the PK days, study medication intake with a standardized 
breakfast (626 kcal) and 240 mL of water was witnessed. 
 
Analytical and PK methods 
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at each 
time-point, immediately inverted several times and then kept on ice or refrigerated until 
centrifugation. Within 30 minutes of blood collection, each blood sample was centrifuged 
for 10 minutes at 2000 g at 4°C. Plasma was then aliquoted equally into three 2.0 mL tubes 
(Sarstedt, Germany) and stored at -20°C. 
Samples were shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The 
laboratory participates in an external quality assurance scheme (KKGT, the Netherlands). 
 
Quantification of ethinylestradiol, levonorgestrel, atazanavir and cobicistat 
Concentrations of ethinylestradiol, levonorgestrel, atazanavir and cobicistat in plasma were 
measured using validated high-pressure liquid chromatography–tandem mass 
spectrometry methods.9 The lower limits of quantification (LLQ) for the plasma analyses 
was 5pg/mL for EE, 0.240 ng/mL for LNG, 10 ng/mL for atazanavir, and 5 ng/mL for 
cobicistat. For concentrations below the assay limit of quantification, a value of one-half of 
the quantification limit was used.  
Accuracy (percentage bias) was between 0.61% and 3.28% (EE), -0.42% and 1.5% (LNG), 
4.70% and 6.36% (ATV), and 6.45% and 8.07% (cobicistat) and precision was less than 
8.0% (EE), 3.1% (LNG), 6.3% (ATV), and 8.0% (cobicistat). 
 
Data analysis 
The calculated PK parameters for plasma EE, LNG, ATV and cobicistat were the plasma 
concentration measured 24 hours after the observed dose (C24h), the Cmax and the AUC 
from 0 to 24 hours (AUC0–24). All PK parameters were calculated using actual blood 
sampling time and non-compartmental modeling techniques (WinNonlin Phoenix, version 
6.1; Pharsight, Mountain View, CA). Descriptive statistics, including geometric mean (GM) 
and 95% confidence intervals (95% CI) were calculated for EE, LNG, ATV and cobicistat 
plasma PK parameters. Each drug PK parameter during the co-administration period was 
compared to the unaccompanied drug PK parameter by calculating GM ratios and 90% CI 
(co-administered/alone) using excel.  
Inter individual variability in drug PK parameters was expressed as a percentage coefficient 
of variation [CV, (standard deviation/mean)×100]. 
 
ETHICS 
The study protocol was approved by the Westminster Research Ethics Committee, London, 
United Kingdom, as well as by the Medicines and Healthcare products Regulatory Agency 
(MHRA) in the United Kingdom. The study was conducted according to Good Clinical 
Practice and the Declaration of Helsinki (EudraCT Number: NCT02697851). 
  
Results 
 
Study population 
Sixteen healthy female volunteers were screened, 13 were enrolled (one was not 
eligible and 2 withdrew consent for personal reasons). Nine subjects completed the 
intensive PK day 14 (five in group 1, four in group 2), eight completed day 35 (four 
in each group) and six completed all PK phases (four in group 1, two in group 2). 
Overall, seven participants withdrew consent; five because of adverse events and 
two before starting the study medication. In those who completed all PK phases, 
median (range) age and median BMI were 31 (19-35) years, and 24 (19-29) kg/m2, 
respectively. Four participants described themselves as Caucasians, six as black 
African, and one as Hispanic. Participant demographics, withdrawals and 
withdrawal reasons are summarized in Table 1. 
Pharmacokinetic results 
Pharmacokinetic data for all four drugs are summarized in Table 2.  
 Ethinylestradiol plasma pharmacokinetics 
EE GM plasma concentration versus time curves, with and without ATV/cobicistat, 
are shown in Figure 1. Geometric mean ratios (GMR, with versus without 
ATV/cobicistat) and 90% CI of EE Cmax, AUC0-24, C24h were 1.05 (0.92-1.19), 1.01 
(0.88-1.22), 0.75 (0.60-0.93). 
 Levonogestrel plasma pharmacokinetics 
LNG GM plasma concentrations versus time, with and without ATV/cobicistat are 
shown in Figure 2. GMR (90% CI) of LNG Cmax, AUC0-24, C24h were 0.83 (0.68-1.02), 
0.92 (0.71-1.18), 1.01 (0.73-1.38). 
 Atazanavir plasma pharmacokinetics 
GMR (90%) CI of ATV Cmax, AUC0-24, C24h were 0.75 (0.60-0.95), 0.78 (0.64-0.96), 
0.89 (0.72-1.11). 
 Cobicistat plasma pharmacokinetics 
GMR (90% CI) of cobicistat Cmax, AUC0-24, C24h were 0.88 (0.8-0.97), 0.85 (0.77-
0.95), 0.89 (0.66-1.21).  
 
Safety and tolerability 
Five participants withdrew consent from the study secondary to side effects; of 
those, data on the reason are available for three, and are listed in Table 1. No 
grade 3 or 4 adverse events or laboratory abnormalities were observed in the 
women who completed the study. 
  
DISCUSSION 
 
To our knowledge, this is the first study to investigate the PK of a combined 
contraceptive pill co-administered with ATV/cobicistat. Microgynon (EE/LNG), used 
in our study, is the leading contraceptive pill prescribed in the UK.25 
The estrogens and progestogens (some of which are ingested as inactive prodrugs) 
in oral contraceptives undergo extensive first-pass metabolism by phase I and II 
microsomal enzymes in the small intestinal mucosa and liver before reaching the 
systemic circulation,26, 27 leading to a significant susceptibility to DDI.   EE is 
predominantly metabolised by CYP3A4 and CYP2C9 but glucuronidation pathways 
also play a role in clearance.28 Our findings show that EE C24h decreased by only 
25% with ATV/cobicistat compared with 37% with ATV/ritonavir in previous 
studies.20 This may be explained by the fact that, unlike ritonavir, cobicistat does not 
induce UGT1A1 (nor CYP2C9).23 There was no reduction seen in AUC nor Cmax. 
The EE component of the COCP, as well as inhibiting follicular development of 
ovulation, is responsible for endometrial stability and a significant reduction in levels 
can lead to breakthrough bleeding,11 itself likely to impact on adherence to 
contraception and risks of pregnancy.  
Our study is the first to assess the PK of LNG during co-administration with cobicistat 
and we found no significant changes in its concentration (GMR C24h 1.01). LNG is a 
second generation progestin17 whose main metabolism is through hydroxylation and 
glucoronidation, which cobicistat is not thought to affect. This is important because 
an important factor in the efficacy of the combined OCP is the progestogen-
mediated suppression of the luteinizing hormone (LH) surge (although the minimum 
level of progestin needed for efficacy is not completely known).29, 30 Decreases in 
progestin levels could therefore potentially impact contraceptive efficacy. 
Conversely, increases in concentrations (as seen with ritonavir boosted ATV) may 
lead to toxicity such as nausea, weight gain and acne, which in turn can impact 
adherence. LNG is the progestin contained in one brand of emergency 
contraceptive pill; the fact that no changes in drug concentrations were seen with 
ATV/cobicistat is therefore reassuring, and consistent with the knowledge that LNG 
is not subject to any first-pass effect.31 It is a substrate of glucuronosyltransferases32 
and co-administration with cobicistat would not affect this metabolic pathway, while 
ritonavir might induce it. Finally, it is worth mentioning that although the latter 
metabolic pathway is well known, ATV did not lead to an increase of LNG 
concentrations. 
In both groups, ATV concentrations remained above the in vivo suggested minimum 
effective concentration for for wild type HIV  (MEC = 150 ng/mL).18  
There are limitations to this study. The subjects were HIV negative healthy 
volunteers. As such, PK or pharmacodynamic conclusions cannot be robustly drawn 
and the practical implications of these PK observations are unknown. Clinical 
outcome data are required in large cohorts of HIV infected participants, and studies 
investigating pharmacodynamics endpoints (such as failure of viral suppression, 
HIV-related clinical disease progression or unintended pregnancy) are needed in 
order to draw definite conclusions on how likely a contraceptive is to fail in the 
context of a particular ARV combination. It is also important to remember that 
efficacy rates of user dependent contraception differ between perfect use (as seen 
in a clinical trial) and real life use.  
Possibly also related to the fact that this study involved healthy volunteers, the drop 
out rate was high. Five/11 participants withdrew consent due to side effects, which 
included a rash and gastrointestinal symptoms. In a real-life clinical setting, the 
onset of COCP or ARVs is commonly associated with mild side effects, which do 
not normally persist beyond three to six months, at which point an alternative is 
usually offered. This option to persist and assess was not available in the context of 
this study. As a result, the numbers of participants with a complete data set was low.  
Nevertheless, this is the first study to offer PK data on EE/LNG and ATV/cobicistat 
co-administration. We demonstrated a lesser decrease in EE with ATV/cobicistat 
than seen with ATV/ritonavir and no changes in LNG concentrations. This data is 
important in informing physicians who need to discuss and chose safe and reliable 
contraception with their female patients living with HIV.  
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Legends to Tables and Figures 
 
Table 1: Participant demographics, withdrawals and withdrawal reasons. 
ID = study identification, BMI = body mass index, G = group, D = day, n/a = not 
available. 
 
Table 2: Summary of pharmacokinetic data for all four drugs. 
EE = ethinylestradiol, LNG = levonorgestrel, ATV = atazanavir, CV = coefficient of 
variation, GM = geometric mean, GMR = geometric mean ratio, CI = confidence 
interval, Cmax = maximum concentration, AUC0-24 = area under the curve from 0 to 
24 hours, C24h = concentration at 24 hours post-dose. 
 
Figure 1: Ethinylestradiol (EE) geometric mean (GM) plasma concentration versus 
time curves with and without atazanavir (ATV)/cobicistat. 
 
Figure 2: Levonorgestrel (LNG) geometric mean (GM) plasma concentration 
versus time curves with and without atazanavir (ATV)/cobicistat. 
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